Tiago Fauth
Stock Analyst at Wells Fargo
(2.36)
# 2,587
Out of 5,150 analysts
152
Total ratings
43.97%
Success rate
-0.66%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $149.88 | +44.78% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $13.71 | +31.29% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $490.21 | -15.55% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $2.95 | +238.98% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $64.29 | +13.55% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $34.38 | -9.83% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $327.30 | +20.68% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $21.80 | +198.17% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $66.54 | +14.22% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.62 | +24.56% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $27.41 | +268.48% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.29 | +132.56% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $13.77 | +88.82% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.33 | +18.63% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $61.10 | +22.75% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $14.00 | +342.86% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $241.38 | -63.13% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $30.39 | +67.82% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $60.43 | +98.58% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $27.08 | -85.23% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.66 | +426.32% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $57.54 | +421.38% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $8.55 | +204.09% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.63 | +671.35% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $19.86 | +307.85% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.17 | +4,543.06% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.49 | +839.60% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $2.19 | +1,452.51% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $29.68 | +405.39% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $41.69 | -30.44% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.81 | +618.23% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.19 | +493.61% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.92 | +118.48% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $749.56 | -54.64% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $379.27 | -31.71% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $149.88
Upside: +44.78%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $13.71
Upside: +31.29%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $490.21
Upside: -15.55%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.95
Upside: +238.98%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $64.29
Upside: +13.55%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $34.38
Upside: -9.83%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $327.30
Upside: +20.68%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $21.80
Upside: +198.17%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $66.54
Upside: +14.22%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.62
Upside: +24.56%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $27.41
Upside: +268.48%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.29
Upside: +132.56%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $13.77
Upside: +88.82%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.33
Upside: +18.63%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $61.10
Upside: +22.75%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $14.00
Upside: +342.86%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $241.38
Upside: -63.13%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $30.39
Upside: +67.82%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $60.43
Upside: +98.58%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $27.08
Upside: -85.23%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.66
Upside: +426.32%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $57.54
Upside: +421.38%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $8.55
Upside: +204.09%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.63
Upside: +671.35%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $19.86
Upside: +307.85%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.17
Upside: +4,543.06%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.49
Upside: +839.60%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $2.19
Upside: +1,452.51%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $29.68
Upside: +405.39%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $41.69
Upside: -30.44%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.81
Upside: +618.23%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.19
Upside: +493.61%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.92
Upside: +118.48%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $749.56
Upside: -54.64%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $379.27
Upside: -31.71%